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schizophrenia in Brazil reached to US$195,885,270.68. Of this amount, only US$ 
R$7,496,366.58 (3.83%) came from states and US$188,388,904.10 (96.17%) from 
MoH resources. This value represented 11% of MoH’s annual budget for 
acquisition of high-cost medicines. Olanzapine and quetiapine accounted for 
nearly 81% of total expenses with atypical antipsychotics (US$103,763,938.18 and 
US$55,419,573.97, respectively). The others agents represented lower impacts: 
US$23,199,945.99 (ziprasidone), US$12,881,256.10 (clozapine) and US$620,556.45 
(risperidone). CONCLUSIONS: The data demonstrate the impact of financial 
resources applied in atypical antipsychotics to treat schizophrenia in SUS. In this 
scenario, strategies to strengthen the health industrial complex and to optimize 
resource allocation, as the current production of olanzapine and quetiapine in 
public pharmaceutical laboratories, are very desirable.  
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OBJECTIVES: Prescription drug monitoring programs (PDMPs) can help 
pharmacists provide appropriate care to patients taking controlled prescription 
drugs (CPDs). Study objectives were to 1) describe pharmacists’ views on 
mandating PDMP use and providing opioid addiction counseling; 2) determine 
what demographic and practice characteristics are associated with CPD-related 
continuing education (CE) hours; and 3) describe actions associated with 
dispensing CPDs. METHODS: This cross-sectional mail survey of 998 randomly 
selected Texas community pharmacists was part of a larger study to examine 
pharmacists’ intention to utilize a PDMP. Data were collected anonymously from 
2/12-4/12. Descriptive and inferential statistics were used to address the study 
objectives. RESULTS: The useable response rate was 26.2%. Pharmacists were 
more supportive of mandating PDMP use for physicians (4.1±1.2) than for 
pharmacists (3.2±1.5), (1=strongly disagree to 5=strongly agree). Male, BS degreed, 
pharmacy owners (vs. managers) and ≥50 year old pharmacists reported 
significantly (p<0.05) more CE hours related to prescription opioid abuse and 
pain management. CE was significantly correlated with pharmacists’ agreement 
to provide counseling (p=0.02). More than 45% of pharmacists were “always” 
prompted to use the PDMP when: patients paid cash (48.1%), prescription had 
mistakes (68.1%) and early refill request were made (66.3%). Prior to dispensing 
CPDs, more than 45% of pharmacists “always” consulted patient records (49.2%), 
verified prescribers DEA (48.0%) and patient identification (47.5%). Almost 40% of 
pharmacists “never” discussed buprenorphine/naloxone with patients or 
prescribers if they suspected abuse; instead 92.3% refused to fill the prescription 
and 44.0% were neutral regarding notifying law enforcement and counseling 
(35.1%). Pharmacists with a BS degree expressed higher agreement with opioid 
addiction counseling (p=0.02). CONCLUSIONS: Older male pharmacists received 
more CE and seemed more willing to provide counseling to patients with opioid 
addiction. As PDMP use becomes more prevalent, pharmacists should be 
prepared to interact and counsel patients with addictive patterns of prescription 
opioid use.  
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OBJECTIVES: Quantify changes in health care resource utilization and costs 
following clozapine initiation in Medicaid beneficiaries with schizophrenia or 
schizoaffective disorders. METHODS: Data were derived from the MarketScan 
Medicaid database for dates of service between 2007-2009. Patients had >1 
clozapine claim without clozapine use in the 12 months prior to the initiation 
(index) date; had >1 diagnosis of schizophrenic disorder (ICD-9-CM=295.xx) in the 
12 months prior (preperiod) through 12 months after (postperiod) index; were 
continuously enrolled throughout the preperiod and postperiod; and were aged 
18-64 years. Outcome measures included health care payments and resource 
utilization in 3 categories: all-cause (primary outcome); disease-specific (mental 
health and schizophrenia diagnoses); and cardiometabolic (cardiovascular or 
diabetes diagnoses). Comparisons of preperiod versus postperiod values were 
made using paired t-tests and McNemer’s tests for continuous and categorical 
variables, respectively. RESULTS: Mean patient age (n=1,045) was 36.32 years; 
56.1% male. Following clozapine initiation, mean 12-month all-cause health care 
payments did not change significantly (preperiod=$27,407, postperiod=$26,518, 
P=0.415). Payments for mental health and schizophrenia-related claims declined 
by 13.6% (P<0.001) and 11.7% (P=0.016), respectively. Increases in outpatient costs 
were offset by inpatient service cost reductions; significant declines were 
observed from the preperiod to the postperiod in the percentages of patients 
with hospitalizations for all causes (40.6% vs. 35.7%, P=0.003), mental disorders 
(40.2% vs. 35.1%, P<0.001), and schizophrenia (35.9% vs. 31.6%, P=0.007). No 
significant changes in cardiovascular or diabetes costs were observed. 
CONCLUSIONS: Clozapine initiation was associated with reductions in disease-
specific health care utilization and costs without increased cardiometabolic 
costs.  
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OBJECTIVES: To identify sociodemographic factors associated with off-patent 
brand antidepressants utilization. METHODS: Secondary data analysis was 
conducted using 2010 Medical Expenditure Panel Survey (MEPS). Although the 
following medications were available in generic products as of 2010: Venlafaxine, 
Fluoxetine, Paroxetine, Bupropion, Citalopram, Sertraline, Mirtazapine. 216 
unique participants were identified as brand users out of 1694 participants 
taking the aforementioned medications. Race, family’s total income, health 
insurance coverage, gender, and age were categorized and included first in 
bivariate logistic regression to identify significant predictor variables for the 
utilization of off-patent brand antidepressants. Charlson Co-morbidity Index 
(CCI) score was calculated using ICD9CODX variable and the total score was 
included in the analysis. The significant predictor variables were then included 
in multivariable logistic regression model. RESULTS: Brand users were more 
likely to be White (non-Hispanic) (OR=2.158, 95% CI=1.27-3.659), female 
(OR=1.678, 95% CI=1.109-2.537), having private insurance (OR=1.481, 95% 
CI=1.028-2.134) and from upper middle income class (family’s total income: 
$100,000-$500,000) (OR=1.595, 95% CI=1.030-2.471). However, race (White (non-
Hispanic)) and gender (female) variables were found to be significantly 
associated with brand utilization (P<0.05) after accounting for income and 
insurance coverage. Participants with zero CCI score (absence of CCI’s 17 chronic 
medical conditions) were more likely to be brand user (OR=1.286, 95% CI=0.901-
1.837) although this was not found to be statistically significant (P>0.05). 
CONCLUSIONS: Despite some case reports and bioequivalence studies 
suggesting a disadvantage in efficacy and tolerability of generic medications 
compared with brand-name equivalents, the preponderance of evidence 
suggests that generic antidepressants provide cost savings over brand-name 
medications and equal discontinuation rate. Racial as well as gender differences 
in brand antidepressants preferences were identified, which will possibly help 
clinicians counsel patients with higher likelihood of utilizing off-patent brand-
name antidepressants to help dispel any misconceptions about generic 
antidepressants’ efficacy.  
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OBJECTIVES: The Centers for Medicare and Medicaid Services recently increased 
public access to its Medicare data with the release of Basic Stand Alone (BSA) 
Medicare Claims Public Use Files. This study sought to compare the estimates 
obtained from new BSA claims and public survey data on the number of 
prescriptions per visit associated with Alzheimer's disease (AD) among elderly 
patients in the ambulatory setting. METHODS: Visits of Medicare beneficiaries 
aged 65+ with AD (ICD-9-CM 290, 294, 331, or disease indicator variable) were 
identified in two available data years (2008 and 2010) of BSA claims and two 
national surveys (National Ambulatory Medical Care Survey [NAMCS] and 
outpatient component of National Hospital Ambulatory Medical Care Survey 
[NHAMCS]) of the same years. Descriptive statistics were compared between the 
claims and survey sources on patients’ demographics, co-morbidities, and drug 
use. Numbers of prescriptions per visit were compared between patients with 
and without AD through multivariate regressions (Generalized Linear Model with 
Poisson distribution), controlling for age, sex, and a series of co-morbidities. 
RESULTS: Ambulatory visits by Medicare-covered elderly AD patients were 
identified. As compared to the two surveys, the claims source involves more 
female beneficiaries (64.8% vs. 52.9%) and has higher proportion of patients with 
other chronic conditions in addition to AD (88.2% vs. 67.8%). The top 3 co-
morbidities in the claims source are myocardial ischaemia, heart failure and 
diabetes, while the list is different in surveys as arthritis, diabetes and cancer. 
AD contributes an increased drug use of 2.3 prescriptions per visit in claims and 
1.1 prescriptions in surveys, as predicted by multivariate regressions. 
CONCLUSIONS: This study is an initial exploration comparing the new Medicare 
claims source with national surveys on AD patients’ drug use. Further 
evaluations are needed to inform the use of this new public data source in health 
services research.  
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OBJECTIVES: Considering depression as a major public health problem 
worldwide, the aim of our study was to determine the total utilization and 
pattern of use of antidepressants in Serbia in correlation with Finland. 
METHODS: The data on utilization of antidepressant drugs (ATC group N06) 
during the four-year period (2006-2010) were retrieved by a retrospective, 
observational, population-based study. The ATC/DDD methodology was applied 
and the results were expressed in defined daily doses per 1000 inhabitants per 
day (DID). RESULTS: During the observed period of time, the overall utilization of 
antidepressants showed a modest tendency to increase in both countries (12.2% 
in Finland and 15.93% in Serbia). In 2010, overall utilization of antidepressants in 
Serbia (11,67 DID) appeared to be 6 times lower than in Finland (68.83 DID). 
Throughout the whole studied period, the selective serotonine reuptake 
